Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Suicidal Ideation in Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2018
A subset of major depressive disorder (MDD) patients experience suicidal ideation (SID). Because of the potential lethality of SID, SID in MDD is a highly drug-treated condition that uses an array…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…
Obsessive-Compulsive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2018
For the estimated 2.7 million people in the United States who suffer from obsessive-compulsive disorder (OCD), prescription pharmacological therapy involves the use of several approved therapies (e…
Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…
Scleroderma (Systemic Sclerosis) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2018
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…
Borderline Personality Disorder | Treatment Algorithms | Claims Data Analysis | US | 2018
Treatment of borderline personality disorder is multimodal, involving psychotherapy and prescription pharmacotherapy. Prescription drug treatment involves an array of drug classes, including, but…
Systemic Lupus Erythematosus | Access and Reimbursement | Including Lupus Nephritis | EU5 | 2018
Thesystemic lupus erythematosus (SLE)therapy market in the five major pharmaceutical markets in Europe (EU5) is mostly served by off-label therapies.Benlysta is the only drug approved for SLE in…